| Prostate cancer treatment cuts hot flashes
ROCHESTER, Minn., June 4: A U.S. study finds use of low doses of an epileptic seizure medication can significantly reduce the occurrence of hot flashes in prostate cancer patients.The North Central Cancer Treatment Group researchers based at the Mayo Clinic found use of the drug gabapentin that's also used to treat nerve pain caused by shingles substantially reduces hot flashes in men undergoing anti-hormonal treatment, or androgen-deprivation therapy, for prostate cancer.The investigators found gabapentin cut the frequency and intensity of hot flashes up to 46 percent in men receiving androgen deprivation therapy."To my knowledge, this is the first non-hormonal treatment of hot flashes in men, where results from a placebo-controlled trial are positive enough to support that a non-hormonal medication can be used to help some of our patients," lead investigator Dr.
Japanese, US lung cancer victims studied
ANN ARBOR, Mich., June 4 (UPI) -- A U.S. study has determined why lung cancer drugs work better in Japanese patients than they do in U.S. lung cancer patients. A groundbreaking 2006 international study found a group of Japanese patients with advanced non-small cell lung cancer survived longer -- and had a higher rate of side effects -- than U.S. patients with the same diagnosis, when both groups were given two well-known drugs for the disease. Now, a U.S. follow-up study suggests the reasons appear to lie in subtle variations in certain genes that govern how the body metabolizes chemotherapy drugs. The discovery that Japanese and U.S. patients, matched in age, gender and other respects, had differences in key metabolism-related genes is the latest result from a seven-year collaboration between the Southwest Oncology Group of Ann Arbor, Mich., and two clinical trials groups in Japan.
Canine Cancer Cure - Human Benefit UK Symposium - Effort to Cure ...
LONDON and DENVER, June 29 /PRNewswire/ -- On July 12, a one-day symposium, hosted by the Royal Veterinary College and Morris Animal Foundation, will address the number one cause of death in dogs over the age of two -- cancer -- as well as "translational" cancer treatment research, where the same treatments being developed to help dogs suffering from cancer are being successfully applied to humans, especially children. This is the single most intensive, dedicated event related to this subject ever undertaken in the United Kingdom. U.S.-based, Morris Animal Foundation (MAF) will announce its Cure Canine Cancer Campaign to the United Kingdom. One in four dogs in the UK and worldwide die of cancer; many more suffer its devastating effects. "With canine (comparative) cancer research being a major part of RVC's future Clinical Research Strategy and looking to help coordinate other critical cancer research efforts in the UK and worldwide, we are excited to be host of this very important and valuable MAF cancer research symposium," says Professor Jonathan Elliott, vice principal -- research, Royal Veterinary College.
|
